{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:42:28Z","timestamp":1793227348023,"version":"4.5.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune system detects foreign pathogens, distinguishes them from self-antigens and responds to defend human body. When this self-tolerance is disrupted, the overactive immune system attacks healthy tissues or organs and the autoimmune diseases develop. B cells and plasma cells contribute a lot to pathogenesis and persistence of autoimmune diseases in both autoantibody-dependent and autoantibody-independent ways. Accumulating data indicates that treatments aiming to eliminate antibody-secreting cells (B cells or plasma cells) are effective in a wide spectrum of autoimmune diseases. Monoclonal antibodies (mAbs) deplete B cell lineage or plasma cells by signaling disruption, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Engineered-T cells armed with chimeric antigen receptors (CARs) have been adopted from field of hematological malignancies as a method to eliminate B cells or plasma cells. In this review, we update our understanding of B cell depletion therapies in autoimmune diseases, review the mechanism, efficacy, safety and application of monoclonal antibodies and CAR-based immunotherapies, and discuss the strengths and weaknesses of these treatment options for patients.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1126421","type":"journal-article","created":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T09:44:25Z","timestamp":1676195065000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?"],"prefix":"10.3389","volume":"14","author":[{"given":"Zheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jaci.2009.12.980","article-title":"Overview of the immune response","volume":"125","author":"Chaplin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1972595","article-title":"Autoimmune diseases: the failure of self tolerance","volume":"248","author":"Sinha","year":"1990","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1586\/eci.11.88","article-title":"Etiology of autoimmune disease: past, present and future","volume":"8","author":"Alzabin","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1196\/annals.1361.044","article-title":"IL-10 and the cytokine network in the pathogenesis of human autoimmune hemolytic anemia","volume":"1051","author":"Toriani-Terenzi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000468928","article-title":"Thyroid autoimmunity and thyroid cancer: Review focused on cytological studies","volume":"6","author":"Boi","year":"2017","journal-title":"Eur Thyroid J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2017.09.007","article-title":"Drivers of the immunopathogenesis in systemic lupus erythematosus","volume":"31","author":"Rose","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00521","article-title":"Thyroid autoimmunity: Role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases","volume":"8","author":"Frohlich","year":"2017","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.8.3912","article-title":"B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice","volume":"161","author":"Serreze","year":"1998","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.11.009","article-title":"CD19(+)CD24(hi)CD38(hi) b cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients","volume":"32","author":"Blair","year":"2010","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4857","article-title":"B cells amplify IFN-gamma production by T cells via a TNF-alpha-mediated mechanism","volume":"179","author":"Menard","year":"2007","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: the first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo-Lopez","year":"2000","journal-title":"Curr Pharm Biotechnol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"179ps7","DOI":"10.1126\/scitranslmed.3005568","article-title":"Cell-based therapeutics: the next pillar of medicine","volume":"5","author":"Fischbach","year":"2013","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1293\/tox.2015-0031","article-title":"Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies","volume":"28","author":"Suzuki","year":"2015","journal-title":"J Toxicol Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human b cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-005-6192-2","article-title":"Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies","volume":"24","author":"Iannello","year":"2005","journal-title":"Cancer Metastasis Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","article-title":"Rituximab for rheumatoid arthritis","volume":"2","author":"Cohen","year":"2015","journal-title":"Rheumatol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"French Study group on autoimmune bullous skin, first-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"New Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker526","article-title":"B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels","volume":"51","author":"Lazarus","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: relationships among serum b lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.06.001","article-title":"High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis","volume":"81","author":"Gardette","year":"2014","journal-title":"Joint Bone Spine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21865","article-title":"Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital","volume":"65","author":"Couderc","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior b-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9777","article-title":"Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma","volume":"29","author":"Tarella","year":"2011","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","article-title":"New anti-CD20 monoclonal antibodies for the treatment of b-cell lymphoid malignancies","volume":"25","author":"Robak","year":"2011","journal-title":"BioDrugs"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"New Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"New Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a target for therapeutic type I and II monoclonal antibodies","volume":"47","author":"Beers","year":"2010","journal-title":"Semin Hematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"New Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"102512","DOI":"10.1016\/j.msard.2020.102512","article-title":"Impact of the COVID-19 pandemic on the health care of >1,000 people living with multiple sclerosis: A cross-sectional study","volume":"46","author":"Vogel","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/ar3179","article-title":"Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of b-cells in systemic lupus erythematosus","volume":"12","author":"Daridon","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B45","first-page":"622","article-title":"Systemic lupus erythematosus: Epratuzumab not effective in phase III trials","volume":"12","author":"Onuora","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: Results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(04)00079-2","article-title":"Reduced competitiveness of autoantigen-engaged b cells due to increased dependence on BAFF","volume":"20","author":"Lesley","year":"2004","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive b cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis b lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/039463200702000101","article-title":"BAFF and rheumatic autoimmune disorders: implications for disease management and therapy","volume":"20","author":"Bosello","year":"2007","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in b cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.11.7276","article-title":"Regulated expression of BAFF-binding receptors during human b cell differentiation","volume":"179","author":"Darce","year":"2007","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.12.035","article-title":"B cell alterations during BAFF inhibition with belimumab in SLE","volume":"40","author":"Ramskold","year":"2019","journal-title":"EBioMedicine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1756286418761697","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"103352","DOI":"10.1016\/j.msard.2021.103352","article-title":"Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the n-MOmentum study","volume":"57","author":"Flanagan","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01187","article-title":"The multi-faceted ecto-enzyme CD38: Roles in immunomodulation, cancer, aging, and metabolic diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: An immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"New Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"New Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948144","article-title":"Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies","volume":"50","author":"Cheng","year":"2020","journal-title":"Eur J Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained b cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0232-6","article-title":"T(reg) cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.clim.2013.11.004","article-title":"Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time","volume":"150","author":"Jethwa","year":"2014","journal-title":"Clin Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2567.2008.02813.x","article-title":"Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target","volume":"124","author":"Sojka","year":"2008","journal-title":"Immunology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00043","article-title":"Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity","volume":"10","author":"Romano","year":"2019","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B78","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflamm"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05133-0","article-title":"Tailored treatment strategies and future directions in systemic lupus erythematosus","volume":"42","author":"Nikolopoulos","year":"2022","journal-title":"Rheumatol Int"},{"key":"B82","doi-asserted-by":"publisher","first-page":"102242","DOI":"10.1016\/j.coph.2022.102242","article-title":"Immune tolerance therapies for autoimmune diseases: Shifting the goalpost to cure","volume":"65","author":"Sharkey","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/ni833","article-title":"B cells regulate autoimmunity by provision of IL-10","volume":"3","author":"Fillatreau","year":"2002","journal-title":"Nat Immunol"},{"key":"B84","article-title":"Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors","volume":"52","author":"Sung","year":"1992","journal-title":"Cancer Res"},{"key":"B85","article-title":"Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors","volume":"72","author":"Capone","year":"1984","journal-title":"J Natl Cancer Inst"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1126421\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T09:44:30Z","timestamp":1676195070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1126421\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":85,"alternative-id":["10.3389\/fimmu.2023.1126421"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1126421","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"article-number":"1126421"}}